Stock Ratings | Morgan Stanley maintained its "overweight" rating on Kyverna Therapeutics (KYTX) and raised its price target from $20 to $25, representing a potential upside of 218.88%.
Kyverna Therapeutics, Inc. KYTX | 7.58 7.58 | -2.82% 0.00% Pre |
Capricor Therapeutics, Inc. CAPR | 27.77 28.32 | -3.91% +1.98% Pre |
Pharvaris N.V. PHVS | 27.29 27.29 | -0.22% 0.00% Pre |
Solid Biosciences Inc. SLDB | 6.49 6.49 | -8.72% 0.00% Pre |
Inotiv, Inc. NOTV | 0.25 0.25 | -5.74% 0.00% Pre |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
Morgan Stanley: Maintaining an "overweight" rating on Kyverna Therapeutics ( Kyverna Therapeutics(KYTX.US) ), while raising the price target from $20 to $25.
Maxim Group maintains its "buy" rating on Capricor Therapeutics ( Capricor Therapeutics, Inc.(CAPR.US) ), raising its price target from $25 to $50.
Oppenheimer: Maintaining Pharvaris' ( Pharvaris N.V.(PHVS.US) ) rating at "Outperform Market", while raising the price target from $44 to $50.
Needham: A preliminary rating of "buy" for Solid Biosciences(SLDB.US) stock, with a target price of $16.
Lake Street: Maintaining a "buy" rating on Inotiv stock ( Inotiv, Inc. - Common Stock(NOTV.US) ), while lowering the price target from $5 to $3.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| Kyverna Therapeutics(KYTX.US) | to lift | $25.0 | $7.84 | 218.88% | Morgan Stanley |
| Capricor Therapeutics, Inc.(CAPR.US) | to lift | $50.0 | $25.4 | 96.85% | Maxim Group |
| Pharvaris N.V.(PHVS.US) | to lift | $50.0 | $27.69 | 80.57% | Oppenheimer |
| Skyward Specialty Insurance Group Inc.(SKWD.US) | to lift | $80.0 | $47.52 | 68.35% | Citizens |
| Genie Energy Ltd. Series 2012 - A Preferred Stock $0.01 par value(GNE-A.US) | to lift | $17.0 | $11.23 | 51.38% | Guggenheim |
| Solid Biosciences(SLDB.US) | Initial classification | $16.0 | $5.92 | 170.27% | Needham |
| Inotiv, Inc. - Common Stock(NOTV.US) | cut | $3.0 | $0.8789 | 241.34% | Lake Street |
| CANGO INC.(CANG.US) | cut | $3.0 | $1.29 | 132.56% | HC Wainwright & Co. |
| Torrid Holdings(CURV.US) | cut | $2.0 | $1.13 | 76.99% | B of A Securities |
| Torrid Holdings(CURV.US) | cut | $2.0 | $1.13 | 76.99% | Telsey Advisory Group |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Truist Securities: Maintaining a "sell" rating on Airbnb, Inc.(ABNB.US) ), while raising the price target from $104 to $107.
Macquarie: Maintaining a "neutral" rating on Salesforce ( Salesforce.com, inc.(CRM.US) ), while raising the price target from $250 to $265.
Deutsche Bank: Maintaining a "buy" rating on Salesforce ( Salesforce.com, inc.(CRM.US) ) stock, while raising its price target from $340 to $360.
Northland Capital Markets: Maintaining a "Market Match" rating on Salesforce Salesforce.com, inc.(CRM.US) stock, while raising its price target from $264 to $267.
Barclays: Maintaining Salesforce ( Salesforce.com, inc.(CRM.US) ) at "overweight" rating, while raising the price target from $316 to $330.
Goldman Sachs: Maintaining a "buy" rating on CrowdStrike Holdings CrowdStrike(CRWD.US) ), raising its price target from $535 to $564.
Citigroup: Maintaining a "buy" rating on CrowdStrike Holdings CrowdStrike(CRWD.US) ), raising its price target from $575 to $595.
BMO Capital: Maintaining Eli Lilly ( Eli Lilly and Company(LLY.US) ) stock rating at "outperforming the market," while raising the price target from $1,100 to $1,200.
Jefferies: Maintaining a "buy" rating on Macy's ( Macy's Inc(M.US) ), while raising the price target from $18.5 to $26.
Argus Research: Maintaining its "Buy" rating on MongoDB MONGODB(MDB.US) ), while raising its price target from $340 to $488.
Barclays: Maintaining the 3M ( 3M Company(MMM.US) ) rating at "Overweight", while raising the price target from $180 to $190.
UBS: Maintaining a "neutral" rating on Nu Holdings ( Nu Holdings(NU.US) ), while raising its price target from $16 to $18.4.
Mizuho: Maintaining a "neutral" rating on UiPath ( UiPath, Inc.(PATH.US) ), while raising the price target from $14 to $15.
BMO Capital: Maintaining UiPath's ( UiPath, Inc.(PATH.US) ) rating at "Market Match", while raising the price target from $13 to $17.
Canaccord Genuity: Maintaining a "buy" rating on UiPath ( UiPath, Inc.(PATH.US) ), while raising the price target from $15 to $19.
RBC Capital: Maintaining a "sector-match" rating for UiPath ( UiPath, Inc.(PATH.US) ), while raising its price target from $14 to $16.
Morgan Stanley: Maintaining Snowflake(SNOW.US) 's rating at "overweight", while raising the price target from $272 to $299.
Evercore ISI Group: Maintaining Snowflake(SNOW.US) 's rating at "Outperform Market", while raising the price target from $280 to $300.
Wells Fargo: Maintaining Snowflake(SNOW.US) 's rating at "Overweight", while raising the price target from $275 to $290.
Keybanc: Maintaining Snowflake(SNOW.US) 's rating at "Overweight", while raising the price target from $275 to $285.
Stifel: Maintaining a "buy" rating on Snowflake Snowflake(SNOW.US) ) stock, while raising the price target from $260 to $280.
First Coverage
Susquehanna: Initial rating for GE Aerospace ( GE Aerospace(GE.US) ) stock at "positive", with a price target of $350.
Citigroup: JetBlue Airways ( JetBlue Airways Corporation(JBLU.US) ) has a preliminary "sell" rating on its stock, with a target price of $4.1.
JP Morgan: Knife River Corp Ordinary Shares ( Knife River Corp Ordinary Shares(KNF.US) ) has a "neutral" initial rating, with a price target of $83.
Citigroup: Southwest Airlines ( Southwest Airlines Co.(LUV.US) ) initial rating at "neutral", with a price target of $38.
Wells Fargo: Initial rating for Maze Therapeutics ( Maze Therapeutics, Inc.(MAZE.US) ) at "overweight", with a target price of $55.
Goldman Sachs: Initial rating for MBX Biosciences ( MBX Biosciences(MBX.US) ) at "Sell", with a target price of $18.
Guggenheim: A preliminary rating of "buy" for monday.com Ltd.(MNDY.US) ) stock, with a target price of $250.
Canaccord Genuity: Initial rating for MNTN ( MNTN, Inc Class A(MNTN.US) ) stock at "Buy", with a target price of $20.
Baird: Initial rating for O'Reilly ( O'Reilly Automotive, Inc.(ORLY.US) ) at "outperforms the market," with a price target of $115.
reduction
Barclays: Maintaining its "Market-Similar Weight" rating on Arcadia Healthcare ( Acadia Healthcare Company, Inc.(ACHC.US) ), while lowering its price target from $17 to $14.
Citigroup: Maintaining a "neutral" rating on Adobe ( Adobe Systems Incorporated(ADBE.US) ) stock, while lowering its price target from $400 to $366.
Citigroup: Maintaining a "neutral" rating on Alexandria Real Estate ( Alexandria Real Estate Equities, Inc.(ARE.US) ), while lowering its price target from $61 to $52.
UBS: Maintaining a "sell" rating on Campbell Soup ( Campbell Soup Company(CPB.US) ), while lowering the price target from $30 to $28.
Citizens: Maintaining Salesforce's Salesforce.com, inc.(CRM.US) rating at "Outperforming the Market," while lowering the price target from $430 to $405.
BMO Capital: Maintaining its "Outperform" rating on Salesforce Salesforce.com, inc.(CRM.US) ) stock, while lowering its price target from $280 to $275.
Baird: Maintaining Salesforce's Salesforce.com, inc.(CRM.US) rating at "Outperforming the Market," while lowering the price target from $325 to $315.
Truist Securities: Maintaining a "buy" rating on Salesforce ( Salesforce.com, inc.(CRM.US) ) stock, while lowering the price target from $400 to $380.
Evercore ISI Group: Maintaining Salesforce's Salesforce.com, inc.(CRM.US) rating at "Outperforming the Market," while lowering the price target from $360 to $340.
Citigroup: Maintaining its "Buy" rating on Oracle Oracle Corporation(ORCL.US) , while lowering its price target from $415 to $375.
Barclays: Reduced Pentair Pentair plc(PNR.US) ) stock rating to "market-weighted", lowering its price target from $127 to $115.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.